BetterLife Pharma Inc. (BETRF)
| Market Cap | 38.45M +304.5% |
| Revenue (ttm) | n/a |
| Net Income | -1.39M |
| EPS | -0.01 |
| Shares Out | 161.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47,461 |
| Open | 0.2150 |
| Previous Close | 0.2213 |
| Day's Range | 0.2150 - 0.2396 |
| 52-Week Range | 0.0276 - 0.3311 |
| Beta | 0.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 25, 2026 |
About BetterLife Pharma
BetterLife Pharma Inc., a biotechnology company, engages in the development of psychedelic-derived compounds. It focuses on developing and commercializing BETR-001, a non-hallucinogenic and non-controlled LSD derivative to treat neuro-psychiatric and neurological disorders. Its products also comprise MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation. The company was formerly known as Pivot Pharmaceuticals... [Read more]
News
BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
Vancouver, British Columbia--(Newsfile Corp. - August 24, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological dis...
BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing trea...
BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
Fully non-hallucinogenic, oral, non-scheduled 5-HT2A neuroplastogen differentiates BETR-001 from every other 5-HT2A agonist program; depression and other psychiatric disorders retained as optional fut...
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
Vancouver, British Columbia--(Newsfile Corp. - July 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement ...
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement...
BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") today announced it has closed a CAD $2,000...
BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company f...
BetterLife Pharma Highlights Advantages of BETR-001 -- a Potent Neuroplastogen
VANCOUVER, British Columbia – TheNewswire - December 4, 2025 - BetterLife Pharma Inc. (“BetterLife” or the “Compa ny”) ( CSE: BETR / OTCQB: BETRF / FRA: NPAU) , an emerging biotech company, focused o...
BetterLife Pharma Welcomes Daniel Carcillo as Corporate Advisor
VANCOUVER, British Columbia, November 25, 2025 – TheNewswire - BetterLife Pharma Inc. (“BetterLife” or the “Compa ny”) ( CSE: BETR / OTCQB: BETRF / FRA: NPAU) , an emerging biotech company, focused o...
USPTO Files ISSUE NOTIFICATION for BetterLife's BETR-001 Composition of Matter Patent
VANCOUVER, British Columbia, June 18, 2025 – TheNewswire - BetterLife Pharma Inc. (“BetterLife” or the “Compa ny”) ( CSE: BETR / OTCQB : BETRF / FRA: NPAU) , an emerging biotech company focused on th...
BetterLife provides update on neuroplastogenic activity of BETR-001
BetterLife (BETRF) Pharma recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. The emerging new paradigm in treating psychiatric and neurological disord...
BetterLife comments on CEO’s share position ownership
BetterLife (BETRF) Pharma is issuing the a press release in response to British Columbia Securities Commission’s May 21, 2025 news release. BetterLife announced on July 16, 2024, that it had…
BetterLife provides update of mechanism of action of BETR-001
BetterLife (BETRF) Pharma recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. BetterLife reported that its proprietary compound, BETR-001, is showing v...
BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders
VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company focused on the...
BetterLife Announces Debt Settlements
VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the ...
BetterLife appoints Andre Beaudry as corporate advisor
BetterLife (BETRF) Pharma has appointed Andre Beaudry as Corporate Advisor. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, gover...
BetterLife Pharma Appoints Corporate Advisor
VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company, has announc...
BetterLife appoints Steven Sangha to board of directors
BetterLife (BETRF) Pharma appointed Dr. Steven Sangha to its Board of Directors. Sangha has over 25 years of business experience, including investment banking, business development and asset managemen...
BetterLife Pharma Appoints New Director
VANCOUVER, British Columbia, March 31, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company, is pleased ...
BetterLife Announces Debt Conversions
VANCOUVER, British Columbia, March 10, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on th...
BetterLife Announces Favorable Outcome in New York Legal Claims
VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of B...
BetterLife Obtains Favourable Cardiac Safety Data for BETR-001
VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the...
Ahmad Doroudian Announces Filing of Early Warning Report Related to Ownership of Common Shares of Betterlife Pharma Inc.
VANCOUVER, British Columbia, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Ahmad Doroudian announces that he has filed an early warning report (the "Report") announcing his direct and indirect ownership of 14,250...
Amendment of Disclosures in Past Management Information Circulars
VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR ...
BetterLife Announces Closing of a Private Placement
VANCOUVER, British Columbia, July 02, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the...